^
Association details:
| Biomarker: | FGF2 elevation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) + Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
Published date:
06/24/2020
Excerpt:
Indeed, increased FGF-2 levels in serum and tumor specimens were found in IM-treated mice bearing IM-resistant GIST xenografts, whereas BGJ398 used in combination with IM effectively inhibited their growth.
DOI:
https://doi.org/10.3390/cancers12061674
